Nuvalent (NUVL) Change in Account Payables (2020 - 2026)
Nuvalent's (NUVL) quarterly Change in Account Payables came in at -$7.7 million in Q1 2026, down 136.71% YoY from $20.9 million in Q1 2025, and down 198.39% on a QoQ basis from $7.8 million in Q4 2025.
Analysis
Nuvalent (NUVL) Change in Account Payables (2020 - 2026) Analysis & Trends
Nuvalent (NUVL) has 7 years of Change in Account Payables data on file, last reported at -$7.7 million in Q1 2026.
- Quarterly Change in Account Payables fell 136.71% year-over-year to -$7.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.0 million (down 131.55% YoY) and the FY2025 annual result came in at $24.6 million, up 707.53% from the prior year.
- Change in Account Payables slipped to -$7.7 million in Q1 2026, from $7.8 million in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $20.9 million in Q1 2025 to a low of -$12.8 million in Q2 2025.
- A 5-year average of $1.1 million and a median of $1.4 million in 2022 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2023 — Change in Account Payables jumped 872.48% — and 2024, when it slumped 1996.45%.
- Tracing NUVL's Change in Account Payables over 5 years: stood at $2.5 million in 2022, then tumbled by 120.4% to -$507000.0 in 2023, then tumbled by 1996.45% to -$10.6 million in 2024, then soared by 173.52% to $7.8 million in 2025, then tumbled by 198.39% to -$7.7 million in 2026.
- The last three Change in Account Payables figures came in at -$7.7 million (Q1 2026), $7.8 million (Q4 2025), and $8.7 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -8.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 5.03 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 37.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Nuvalent | 9.75 Bn | 9.75 Bn | - | -7.69 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -7.69 Mn |
| Dec 31, 2025 | 7.81 Mn |
| Sep 30, 2025 | 8.67 Mn |
| Jun 30, 2025 | -12.82 Mn |
| Mar 31, 2025 | 20.94 Mn |
| Dec 31, 2024 | -10.63 Mn |
| Sep 30, 2024 | 8.45 Mn |
| Jun 30, 2024 | -5.99 Mn |
| Mar 31, 2024 | 4.12 Mn |
| Dec 31, 2023 | -507,000.00 |
| Sep 30, 2023 | 1.66 Mn |
| Jun 30, 2023 | 1.68 Mn |
| Mar 31, 2023 | -672,000.00 |
| Dec 31, 2022 | 2.49 Mn |
| Sep 30, 2022 | 592,000.00 |
| Jun 30, 2022 | -218,000.00 |
| Mar 31, 2022 | 1.35 Mn |
| Dec 31, 2021 | 732,000.00 |
| Sep 30, 2021 | -914,000.00 |
| Jun 30, 2021 | 1.63 Mn |